Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Januar 2020 12:01 ET | Quelle: AngioSoma, Inc.

Litigation Settlement Agreement Finished

Houston, TX, Jan. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) founding Director and Chief Executive Officer, Alex Blankenship,...
20. August 2019 11:53 ET | Quelle: AngioSoma, Inc.

AngioSoma Confirms Status of Voting Control

Houston, TX , Aug. 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has filed an amendment to its Form 10-K for the fiscal year ended...
18. Juni 2018 11:44 ET | Quelle: AngioSoma, Inc.

AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug

HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™,...
14. Mai 2018 12:13 ET | Quelle: AngioSoma, Inc.

AngioSoma, Inc. Announces Grant of Patent for Flagship Drug

HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship...